TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07365319: A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.

Sponsor: Eikon Therapeutics · Phase: PHASE2/PHASE3 · Area: ONCOLOGY · Target Enrollment: 750 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$16,514,652

Rescue Site Savings

+$10,878,252

Unlock Full NCT07365319 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07365319 Rescue Dossier →